Clinical trials: Vehicle, completed
Ocular Inflammation
Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery
Evaluation of the clinical safety and efficacy of loteprednol etabonate in an ophthalmic base, when compared to vehicle for the treatment of inflammation following cataract surgery.
- Trial name
- NCT00699153
- Testing
- Loteprednol Etabonate, Vehicle of Ophthalmic Loteprednol Etabonate
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Bausch & Lomb Incorporated
Type 2 Diabetes
-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.
The purpose of this study is to evaluate the impact of different ligands of GPR 119 (a G protein-coupled receptor in the intestine) on the secretion of the incretin hormones, GLP-1 and GIP.
- Trial name
- NCT01043445
- Testing
- GPR 119 agonist, 2-oleyl glycerol, Oleic acid, Vehicle
- Where
- Denmark
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Glostrup University Hospital, Copenhagen
Psoriasis Vulgaris
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.
To assess safety, tolerability and pharmacodynamics effect of treatment with microarray patches containing calcipotriol and betamethasone dipropionate.
- Trial name
- NCT03898583
- Testing
- Microarray patch A, Microarray patch B, Daivobet
- Where
- 2 sites in Germany
- Volunteers
- 15 people
- Sponsor
- LEO Pharma
Lateral Canthal Lines, Crow's Feet
Dose Finding Study In Subjects With Crow's Feet
The purpose of this study is to establish the therapeutic range of ANT-1401 in the treatment of Crow's Feet.
- Trial name
- NCT01951742
- Testing
- ANT-1401, Vehicle
- Where
- 10 sites in United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Anterios Inc.
Atopic Dermatitis
Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102
The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy subjects.
- Trial name
- NCT01423656
- Testing
- LEO 29102
- Where
- United Kingdom
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Facial Papulopustular Rosacea
A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
- Trial name
- NCT03142451
- Testing
- FMX103 minocycline foam 1.5%, Vehicle foam
- Where
- 54 sites in United States
- Volunteers
- 751 people
- Sponsor
- Vyne Therapeutics Inc.
Dermatitis, Atopic
An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of VTP-38543 administered as a cream, twice-daily, for 28 days in otherwise healthy adult…
- Trial name
- NCT02655679
- Testing
- VTP-38543, Vehicle with Transcutol®P, Vehicle without Transcutol®P
- Where
- 12 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- Vitae Pharmaceuticals, Inc.
Diabetes Mellitus, Type 1
What is the Dose Response of Varying Meal Content of Fat on Postprandial Glycaemia in Children With T1DM?
Background: Based on international evidence, current management of people with T1DM on intensive insulin therapy (IIT) use algorithms based on the meal carbohydrate content (MCC) to calculate the prandial insulin dose.
- Trial name
- REQINSOIL (NCT02371694)
- Testing
- Test drink
- Where
- Ireland
- Volunteers
- 30 people
- Sponsor
- Cork University Hospital
Presbyopia
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
This is a 4-visit, multi-center, randomized, double-masked, vehicle-controlled study evaluating the safety and efficacy of CSF-1 in the temporary correction of presbyopia.
- Trial name
- NEAR-2 (NCT04599972)
- Testing
- CSF-1, Vehicle
- Where
- 18 sites in United States
- Volunteers
- 304 people
- Sponsor
- Orasis Pharmaceuticals Ltd.
Allergic Conjunctivitis
Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
The purpose of this study is to evaluate an ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
- Trial name
- NCT01743027
- Testing
- AL-4943A ophthalmic solution, Olopatadine hydrochloride ophthalmic solution, 0.2%, Olopatadine hydrochloride ophthalmic solution, 0.1%
- Volunteers
- 902 people
- Sponsor
- Alcon Research
Dry Eye Syndrome
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects with Dry…
- Trial name
- NCT03404115
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.1%), Vehicle Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 300 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Glaucoma, Ocular Hypertension
Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
The objective of this parallel group study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.
- Conditions
- Glaucoma, Ocular Hypertension, Eye Disease
- Trial name
- NCT02136940
- Testing
- AMA0076
- Where
- 9 sites in United States
- Volunteers
- 103 people
- Sponsor
- Amakem, NV
Amyotrophic Lateral Sclerosis
Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS)
Dysphagia (swallow impairment), dystussia (cough impairment) and respiratory impairment are hallmark features of amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT02710110
- Testing
- PowerLung trainer, Micro Mouth Pressure Meter, Pulmonary Function Testing
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Psoriasis
Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
The objective of this study is to demonstrate that desoximetasone 0.25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01206660
- Testing
- Desoximetasone Spray 0.25%
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy
The purpose of this study is to explore the overall safety profile and durability of efficacy of Engensis (VM202) in painful diabetic peripheral neuropathy.
- Trial name
- NCT04055090
- Testing
- Long-Term Follow-Up of Patients who Received Engensis (VM202)
- Where
- 14 sites in United States
- Volunteers
- 101 people
- Sponsor
- Helixmith Co., Ltd.
Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
- Trial name
- NCT02785159
- Testing
- IDP-118 Lotion, Tazorac Cream, IDP-118 Vehicle Lotion
- Where
- 14 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Dermatitis, Atopic
A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream
This will be an open-label, non-randomized, single-center study to assess the residency of GSK2894512 in the skin of healthy adult male volunteers with normal barrier function.
- Trial name
- NCT02411162
- Testing
- Combination therapy GSK2894512 Cream A + GSK2894512 Cream B, Combination therapy Vehicle Cream A + Vehicle Cream B
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Stiefel, a GSK Company
Head Lice
Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion
Purpose of this study will be to determine the potential of abametapir lotion to induce sensitization by repeated topical application to the healthy skin of humans under controlled conditions.
- Trial name
- NCT02062073
- Testing
- Abametapir Lotion 0.74% w/w, 0.1% sodium lauryl sulfate, saline 0.9%
- Where
- United States
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Hand-foot Syndrome
Acetylated Natural Nucleotides in Treating Hand-foot Syndrome
The clinical trial is planned to investigate the efficacy and safety of acetylated natural nucleotides in treating anti-cancer medications induced hand-foot syndrome (HFS).
- Trial name
- NCT04592731
- Testing
- Gel containing Acetylated Natural Nucleotides, Vehicle Gel
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Nan xu
Moderate to Severe Acne Vulgaris
Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris
This study is being conducted to characterize the safety and tolerability of BOS-356 in adult participants with moderate to severe acne vulgaris following 14 days or 28 days of repeated topical application
- Trial name
- NCT04163263
- Testing
- BOS-356, Vehicle
- Where
- 7 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Boston Pharmaceuticals